Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 34Melanoma 13Carcinoma, Hepatocellular 13Neoplasm Metastasis 12Lung Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Neoplasms 9Esophageal Neoplasms 9Colorectal Neoplasms 6Esophageal Squamous Cell Carcinoma 5Breast Neoplasms 5Recurrence 4Rectal Neoplasms 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Liver Neoplasms 3Head and Neck Neoplasms 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Radiation Pneumonitis 2Prostatic Neoplasms 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neuroblastoma 2

Interventions

Sorafenib 5lenvatinib 2ledipasvir, sofosbuvir drug combination 2halofantrine 2atezolizumab 2Liver Transplantation 2Immunotherapy 2Control Groups 2Blood Specimen Collection 2Bevacizumab 2Antibodies 2veliparib 1trifluridine tipiracil drug combination 1trametinib 1titanium silicide 1sintilimab 1rubitecan 1repotrectinib 1pevonedistat 1pembrolizumab 1ozanimod 1linifanib 1genexol-PM 1fluorocholine 1fisogatinib 1ficlatuzumab 1durvalumab 1camrelizumab 1belinostat 1bavituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Liver Diseases × Immunotherapy × Clear all
NCT05063565 2026-06-01

ROWAN

Boston Scientific Corporation

Phase 2 Active not recruiting
100 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT02989870 2020-06-05

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡